博济医药：王廷春、费米十三号、赵伶俐持股比例拟降至36.88%

Core Viewpoint - The controlling shareholder of Boji Pharmaceutical, Wang Tingchun, along with his concerted parties, plans to reduce their shareholding through a centralized bidding process, impacting the overall shareholding structure of the company [1] Summary by Relevant Sections Shareholding Changes - Wang Tingchun and his concerted parties, Zhao Lingli and Feimi No. 13, will reduce their holdings by 1.161 million shares, which represents 0.30% of the company's total share capital [1] - Due to the exercise of stock options from the 2022 incentive plan, the total share capital of the company has increased, leading to a passive reduction of 0.02% in the shareholding percentage of Wang Tingchun, Feimi No. 13, and Zhao Lingli [1] Current Shareholding Status - After the equity change, the controlling shareholder and his concerted parties will hold a total of 14,226,970 shares, accounting for 36.88% of the company's total share capital [1] - The equity change has reached a threshold of 1% in terms of integer multiples [1] Implementation Status - The reduction plan has not yet been fully implemented [1]